The biological indicator market is wide spread and covers a major share from the diagnostics markets of Oncology, Neurology, Cardiology, Pathology, Metabolic and Genetic diseases, and the clinical development processes. The major type being diagnostic, prognostic and predictive biomarkers, with further segmentation covers Product and Application, Technologies and Disease areas.

The major market driver are rising geriatric population and increase in prevalence and incidence of cancer, neurological disorders, cardiovascular diseases, and other chronic diseases, and the demand in drug discovery. The expanding therapeutic segments of personalized medicine and companion diagnostics, alongwith the regulatory approval for targeted therapies have added the market for biomarkers.

Development costs and high research investment requirements, alongside the complex reimbursement scenarios have been the major market restrains. The regularity landscape of different geographies and sample storage and processing have also added to the negative growth of the Biomarkers market.

The M&A and partnership activities by key players such as Biocartis, Amgen, Roche, AstraZeneca, Nucleix have resulted positive growth.

Few of the keyplayers in the Biomarkers market space include Bio-Rad Laboratories, Merck Millipore, Qiagen, Siemens Healthcare, Abbott, Affymetrix, Signosis, EKF Diagnostics, Biosims Technologies, and Cisbio Bioassays.

References: www.datamintelligence.com; www.globenewswire.com; https://bioinfoinc.com; www.verifiedmarketresearch.com; www.omrglobal.com

Biomarkers in Translational Medicine and Research invites an exclusive Market Insight session involving presentations and discussions from Market Leaders, KOLs, Market Research firms, and all the Key stake holders on the growing potential of Biomarkers and Translational Medicine market space.